RGNX REGENXBIO Inc.

17.30
-0.25  -1.42%
Previous Close 17.55
Open 17.55
Price To book 2.58
Market Cap 458.02M
Shares 26,475,000
Volume 174,350
Short Ratio 7.51
Av. Daily Volume 190,844

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrollment to be initiated 1H 2017.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 2H 2017.
RGX-111
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. Rockville gene therapy company to begin trials for treatment for leading cause of blindness
  2. REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration
  3. REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
  4. REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
  5. D.C.-area biotech stocks fall on Trump's tough talk on industry
  6. REGENXBIO Provides Year-End 2016 Corporate Update
  7. REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements
  8. REGENXBIO Provides Year-End 2016 Corporate Update
  9. REGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : December 23, 2016
  10. REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : December 22, 2016
  11. Hedge Funds Have This To Say About Peapack-Gladstone Financial Corp (PGC)
  12. Hedge Funds Are Betting On Regenxbio Inc (RGNX)
  13. Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors
  14. REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors
  15. ETFs with exposure to REGENXBIO, Inc. : November 23, 2016
  16. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
  17. REGENXBIO INC. Financials
  18. Regenxbio Inc Earnings Call scheduled for 4:30 pm ET today
  19. REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
  20. REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits